Supernus reports 39% revenue growth in Q1 2026, driven by strong sales of key CNS drugs.

Supernus Pharmaceuticals posted $207.7 million in total revenues for Q1 2026, up 39% year-over-year, fueled by a 56% rise in sales of its four growth products including Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company resumed new patient starts for ONAPGO and plans FDA submission for a second supplier by Q3 2026, aiming for approval in mid-2027. Despite an operating loss of $8.3 million, adjusted operating earnings improved to $28.7 million. Supernus reaffirmed its full-year 2026 financial guidance, signaling confidence in continued growth and product execution.